STOCK TITAN

Vanguard disaggregates holdings; reports zero Emergent BioSolutions stake (NYSE: EBS)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Emergent BioSolutions Schedule 13G/A shows The Vanguard Group reports 0 shares beneficially owned of Common Stock as of 03/13/2026, representing 0% of the class. The filing cites an internal realignment and reliance on SEC Release No. 34-39538 that led certain Vanguard subsidiaries to report holdings separately. The form is signed on 03/26/2026 by Ashley Grim, Head of Global Fund Administration.

Positive

  • None.

Negative

  • None.

Insights

Vanguard disaggregated holdings; reports no beneficial ownership in EBS after internal reorganization.

The filing states 0 shares beneficially owned and 0% of the class as of 03/13/2026, citing SEC Release No. 34-39538 for disaggregation of subsidiary reporting. This is an administrative ownership update tied to internal structure changes, not a market transaction.

Cash-flow treatment and trading activity are not described in the excerpt; subsequent filings from Vanguard or subsidiaries may show holdings if they hold shares directly.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026
Emergent Biosolutions Inc

NYSE:EBS

View EBS Stock Overview

EBS Rankings

EBS Latest News

EBS Latest SEC Filings

EBS Stock Data

417.29M
50.41M
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
GAITHERSBURG